News

Personalized RNA vaccine induces T cell responses in melanoma

Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.
Read More

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their
Read More

12. Run for Children 2017

Mainz, June 2017 – On June 10, TRON participated in the charity event „Run for Children®“.
Read More

2017 NMFZ prize awarded to Lena Kranz, PhD

Mainz, June 2017 – Lena Kranz, PhD, has been awarded for her doctoral thesis the 2017 NMFZ prize of the Natural Science and Medical Research Center Mainz (NMFZ), part of the University Medical Center of Mainz.
Read More

Lifetime achievement award to Cornelis Melief

Mainz, May 2017 – On May 10, 2017, Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in cancer immunotherapy research.
Read More

Mustafa Diken on the AACR conference 2017

Mainz, April – Mustafa Diken, PhD, presented on this year’s AACR conference 2017 our recent work on nanoparticles and RNA vaccine for cancer therapy.
Read More

Tracking the immune system with bioinformatic precision

Mainz, April – The 32nd Annual Meeting of the Rheumatology Working Group (ARRP) and the cooperative Rheumazentrum Rheinland-Pfalz e.V. …
Read More

7th Ci3-Cluster conference

Mainz, March 2017 – On March 14, 2017 the 7th Ci3-Cluster conference took place in Mainz. The conference looked back at the successes resulting from the past five years of funding for projects in the Cluster for Individualized ImmunIntervention (Ci3) via the German Ministry for Education and Research (BMBF).
Read More

Personalized Cancer Immunotherapy

Mainz, March 2017 – The Research Institute for Translational Oncology (TRON) and the German Cancer Research Center (DKFZ) in Heidelberg join forces in a newly founded Helmholtz Institute for Translational Oncology (HI-TRON) at the University Medical Center Mainz.
Read More

Special Issue Frontiers in Immunology

Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the
Read More

11 Fakten über Krebs

Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine
Read More

SITO – Seminars in Translational Oncology

Mainz, November 17 – ‘The immune biology of microsatellite instability cancer: Towards a vaccine against HNPCC’, Prof. von Knebel Doeberitz from the Institute of Pathology at the University of Heidelberg will speak in our seminar on Thursday during his visit at TRON.
Read More

SITO – Seminars in Translational Oncology

Mainz, November 10 – ‘Inducing Neoantigens in Therapeutic and Prophylactic Cancer Immunotherapy’, Prof. Eli Gilboa from the Sylvester Comprehensive Cancer Center at the University of Miami will speak in our seminar on Thursday during his visit at TRON.
Read More

SITO – Seminars in Translational Oncology

Mainz, September 29 – ‘Diabetes, beta-cells and reprogramming with mRNA: potential cell-based therapy for diabetes’ Tomáš Koblas of the Institute for Clinical and Experimental Medicine, Prague, will talk at Seminars in Translational Oncology (SITO) during his visit at TRON.
Read More

Author summary of our nature publication at ASGCT

Milwaukee, WI, July 23, 2016 – ‘A message for immunity: Systemic nanoparticle RNA vaccines mimic infection to fight cancer’, The American Society of Gene & Cell Therapy (ASGCT) publishes an author summary of our publication by Lena M. Kranz and colleagues in the renowned scientific journal Nature.
Read More

Lena M. Kranz speaks at PIVAC-16

Winchester, UK, September 13th – ” Systemic nanoparticle RNA vaccines mimic infection to fight cancer”, Lena M. Kranz will speak at the 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16), Session 5.
Read More

Ugur Sahin speaks at WCCS 2016

Vienna, September 01 2016 – TRON Scientific Manager Ugur Sahin will speak at the World Congress on Cancers of the Skin 2016. His talks will cover “Mutanome specific personalized vaccination” (11:30 a.m., 2016-09-01) and “RNA based mutanome specific vaccines – a true personalized therapy” (6:00 p.m., 2016-09-01).
Read More

TRON Publication in Cancer Immunology, Immunotherapy

Mainz, July 15 2016 – “Uptake of synthetic naked RNA by DCs allows antigen expression and induction of T-cell responses in mice” – TRON scientist shed further insight into the underlying mechanism of RNA uptake, translation and antigen presentation upon intradermal administration of antigen-encoding RNA.
Read More

Interview im SWR Fernsehen

Mainz, Juli 15 2016 – „Forschungsergebnisse werden zu Therapieverfahren”, Interview mit TRONs wisschenschaftlichem Direktor Prof. Dr. Ugur Sahin im SWR.
Read More

TRON Seminar in Translational Oncology

Mainz, June 30 2016 – “Tissue-resident regulatory T cells”, Dr. Markus Feuerer from the Helmholtz Young Investigator research group “Immune Tolerance” at the German Cancer Research Center (DKFZ), Heidelberg, Germany is visiting TRON. 5 PM, Lecture Hall Building 205, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
Read More

High Media Coverage for Nature Publication

Mainz, June 02 2016 Breaking News Publication in the renowned Nature journal describes first example of RNA-Lipoplexes as a novel vaccine class that exploit antiviral immune mechanisms for potent cancer immunotherapy. Read more about the media coverage for TRON’s most recent Nature publication here.
Read More

TRON Seminar in Translational Oncology

Mainz, June 09 2016 – “Abrogation of the immunosuppressive tumor-microenvironment in Hepatocellular Carcinoma by targeting Treg and co-inhibitory pathways”, Dr. Jaap Kwekkeboom & Dr. Dave Sprengers from Erasmus MC-University Medical Centre, Rotterdam are visiting TRON. 5 PM, Lecture Hall Building 708, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz
Read More

TRON Seminar in Translational Oncology

Mainz, April 28 2016 – “Exploiting Natural Killer cells for immunotherapy of cancer”, PD Dr. rer. nat. Adelheid Cerwenka from the German Cancer Research Center (DKFZ) is visiting TRON.
Read More

TRON Seminar in Translational Oncology

Mainz, April 7 2016 – “Regulation of tumor immunity by macrophage and eosinophils”, Prof. Günter Hämmerling from the German Cancer Research Center (DKFZ) is visiting TRON.
Read More

Vortrag auf dem World Immune Regulation Meeting

Davos, März 16, 2016 – “Eliciting potent T-cells against individual mutant neoantigens – the mutanome as rich target source for individualized cancer vaccination” Vortrag von Dr. Sebastian Kreiter in der Session “Immune Tolerance” auf dem 10. World Immune Regulation Meeting Davos (CH).
Read More

Vortrag 32. Deutscher Krebskongress in Berlin

Berlin, Februar 25, 2016 – “Neue Methoden zur Identifizierung von Tumorantigenen als Targets für Tumorvakzine” Vortrag von Mathias Vormehr in der Session “Translationale Onkologie” auf dem 32. Deutschen Krebskongress in Berlin.
Read More

TRON / BioNTech in Nature Medicine News

Mainz, February 2016TRON/BioNTech in Nature Medicine News Feature: “Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment”TRONs efforts to develop individualized cancer vaccines based on tumor-specific mutations is covered in a recent News Feature published in Nature Medicine.For more information please click the Link below, which will direct you to the Nature
Read More